N eonatal mortality is increasingly recognized as an important global public health challenge that must be addressed if we are to reduce child health disparities between rich and poor countries. Most of the estimated 4 million neonatal deaths per year occur in low and middle income countries. 1 Three conditions: infection, birth asphyxia, and consequences of premature birth/low birth weight, are responsible for majority of these deaths. More than one-third are estimated to be due to severe infections, and a quarter are due to the clinical syndrome of neonatal sepsis/pneumonia. Case fatality rates for neonatal infections remain high among both hospitalized newborns and those in the community.
The purpose of this supplement is to evaluate available evidence on the burden of disease, etiology, antimicrobial resistance, and potential options for management of neonatal sepsis at the community level. The first 3 papers in this supplement resulted from a comprehensive review of the literature on neonatal sepsis commissioned by the Department of Child and Adolescent Health and Development, World Health Organization (WHO). Thaver and Zaidi 8 report the findings from a review of community-based studies from developing countries to estimate rates of infections and infection-specific mortality. It is clear from this review that data from developing countries are limited in both quality and quantity. Zaidi et al 9 review information about pathogens associated with neonatal sepsis in developing countries. Community-based data are almost completely lacking for the early neonatal period (ie, newborns in the first week of life). Most published data are from hospitals where Klebsiella species, E. coli, and Staphylococcus aureus are the most common causes of infection. Antimicrobial resistance patterns of neonatal pathogens are reported in another paper by Thaver et al 10 These authors cite concerns about the emerging resistance of Klebsiella and E. coli to commonly used antibiotics. Although community-based data were scarce, lower antimicrobial resistance levels in the community are encouraging. Bhutta et al 11 reviewed case management approaches for neonatal sepsis in the community settings of low resource countries. Despite limitations, these approaches hold promise for reducing neonatal mortality in such settings. In 2 papers, Darmstadt et al 12, 13 describe available data on use of oral and injectable antibiotics for the management of neonatal sepsis. They present advantages and disadvantages of various antibiotics and discuss some potential choices for simplified antibiotic regimens for the management of neonatal sepsis. Finally, Bahl et al 14 using the Child and Nutrition Research Initiative (CHNRI) process for identifying priority areas for neonatal sepsis, report that management of neonatal infections in community settings is identified as a priority. Of note however, most top ranked priorities are related to health systems and policy research, perhaps due to limited progress in reducing neonatal mortality.
It is no longer possible to overlook the important contribution of neonatal mortality to overall infant survival. To reduce neonatal mortality caused by infections, we must make a strong case for investment in expanded surveillance activities and in further research on diagnosis, etiology, and optimal management of neonatal sepsis at all levels of the health system, particularly at the community level. High quality data are needed to make policy decisions that can help reduce neonatal mortality. National and international donors must be convinced to invest in research and improved health service delivery at country and global levels. The papers presented in this supplement provide a good basis for initiating this process.
